The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 231-235

  Kim, Young Saing ^a   Sun, Jong Mu ^a   Ahn, Jin Seok ^a   Ahn, Myung Ju ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Folic acid; Non small cell lung cancer; Pemetrexed; Toxicity; Vitamin B12; Vitamin supplementation

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PEMETREXED;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG ERUPTION; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; VOMITING;

FOLIC ACID; NON-SMALL-CELL LUNG CANCER; PEMETREXED; TOXICITY; VITAMIN B12; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DIETARY SUPPLEMENTS; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VITAMINS; YOUNG ADULT;

EID: 84879882632     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.04.011     Document Type: Article

References (27)

1. Gronberg B.H., Bremnes R.M., Flotten O., Amundsen T., Brunsvig P.F., Hjelde H.H., et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:3217-3224.
2. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
4. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644.
5. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009, 14:253-263.
6. Kubota K., Niho S., Enatsu S., Nambu Y., Nishiwaki Y., Saijo N., et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol 2009, 4:1530-1536.
7. Hanauske A.R., Chen V., Paoletti P., Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001, 6:363-373.
8. Molina J.R., Adjei A.A. The role of pemetrexed (Alimta LY231514) in lung cancer therapy. Clin Lung Cancer 2003, 5:21-27.
9. Bajetta E., Celio L., Buzzoni R., Ferrari L., Marchiano A., Martinetti A., et al. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 2003, 14:1543-1548.
10. Rollins K.D., Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005, 27:1343-1382.
11. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
12. Sorensen J.B. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol 2011, 7:919-928.
13. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002, 29:3-7.
14. Lopez-Pousa A., Rifa J., Casas de Tejerina A., Gonzalez-Larriba J.L., Iglesias C., Gasquet J.A., et al. Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care (Engl) 2010, 19:648-655.
15. Crawford J., Dale D.C., Kuderer N.M., Culakova E., Poniewierski M.S., Wolff D., et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008, 6:109-118.
16. Takimoto C.H., Hammond-Thelin L.A., Latz J.E., Forero L., Beeram M., Forouzesh B., et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007, 13:2675-2683.
17. Clarke S.J., Abratt R., Goedhals L., Boyer M.J., Millward M.J., Ackland S.P. Phase II trial of pemetrexed disodium (ALIMTA LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002, 13:737-741.
18. Rusthoven J.J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999, 17:1194.
19. Rinaldi D.A., Kuhn J.G., Burris H.A., Dorr F.A., Rodriguez G., Eckhardt S.G., et al. A phase I evaluation of multitargeted antifolate (MTA LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999, 44:372-380.
20. Niyikiza C., Baker S.D., Seitz D.E., Walling J.M., Nelson K., Rusthoven J.J., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002, 1:545-552.
21. Carmel R., Green R., Rosenblatt D.S., Watkins D. Update on cobalamin, folate, and homocysteine. Hematology Am Soc Hematol Educ Program 2003, 2003:62-81.
22. Green R. Metabolite assays in cobalamin and folate deficiency. Baillieres Clin Haematol 1995, 8:533-566.
23. Vincent M., Dranitsaris G., Verma S., Lau C., Gascon P., Van Belle S., et al. The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Support Care Cancer 2007, 15:265-272.
24. Barrett-Lee P.J., Ludwig H., Birgegard G., Bokemeyer C., Gascon P., Kosmidis P.A., et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006, 70:34-48.
25. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol 2003, 1:18-24.
26. Meertens L., Diaz N., Solano L., Baron M.A., Rodriguez A. Serum homocysteine, folate and vitamin B12 in venezuelan elderly. Arch Latinoam Nutr 2007, 57:26-32.
27. Clarke R., Grimley Evans J., Schneede J., Nexo E., Bates C., Fletcher A., et al. Vitamin B12 and folate deficiency in later life. Age Ageing 2004, 33:34-41.